Pathogenesis of heparin-induced thrombocytopenia and thrombosis

Autoimmunity Reviews

Volumn 1, Issue 3, 2002, Pages 125-132

  Arepally, Gowthami ^a   Cines, Douglas B ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ARGATROBAN; DANAPAROID; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOCYTE FACTOR 4; WARFARIN;

ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; CELL ACTIVATION; CLINICAL FEATURE; ENDOTHELIUM CELL; GANGRENE; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARIN INDUCED THROMBOSIS; HUMAN; IMMUNOPATHOGENESIS; LABORATORY DIAGNOSIS; MONOCYTE; NONHUMAN; SKIN NECROSIS; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 1442265917     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(02)00031-9     Document Type: Review

References (37)

1. Weismann R.E., Tobin R.W. Arterial embolism occurring during systemic heparin therapy. AMA Arch. Surg. 76:1958;219-227.
2. Amiral J., Bridey F., Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemost. 68:(1):1992;95-96.
3. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332:(20):1995;1330-1335.
4. Cines D.B. Heparin-induced thrombocytopenia and thrombosis. Schechter G.P., Broudy V.C., Williams M.E. Hematology 2001. 2001;295-305 American Society of Hematology, Washington, DC.
5. Pouplard C., May M.A., Iochmann S., et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 99:(19):1999;2530-2536.
6. Warkentin T.E., Sheppard J.A., Horsewood P., Simpson P.J., Moore J.C., Kelton J.G. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 96:(5):2000;1703-1708.
7. Konkle B.A., Bauer T.L., Arepally G., et al. Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. Ann. Thorac. Surg. 71:(6):2001;1920-1924.
8. Arepally G.M., Cines D.B. Heparin-induced thrombocytopenia and thrombosis. Clin. Rev. Allergy Immunol. 16:1998;1-11.
9. Warkentin T.E., Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101:(5):1996;502-507.
10. Warkentin T.E., Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344:(17):2001;1286-1292.
11. Griffiths E., Dzik W.H. Assays for heparin-induced thrombocytopenia. Transfusion Med. 7:(1):1997;1-11.
12. Newman P.M., Chong B.H. Further characterization of antibody and antigen in heparin-induced thrombocytopenia. Br. J. Haematol. 107:(2):1999;303-309.
13. Greinacher A., Alban S., Dummel V., Franz G., Muellereckhardt C. Characterization of the structural requirements for a carbohydrate-based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb. Haemost. 74:(3):1995;886-892.
14. Vun C.M., Evans S., Chong B.H. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb. Res. 81:(5):1996;525-532.
15. Mikhailov D., Young H.C., Linhardt R.J., et al. Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia. J. Biol. Chem. 274:(36):1999;25317-25329.
16. Suh J.S., Aster R.H., Visentin G.P. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood. 91:(3):1998;916-922.
17. Ziporen L., Li Z.Q., Park K.S., et al. Defining an antigenic epitope on platelet factor 4 (PF4) associated with heparin-induced thrombocytopenia and thrombosis (HITT). Blood. 92:(9):1998;3250-3259.
18. Li Z.Q., Liu W., Park K.S., et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis (HIT/T) antibodies using KKO, a murine HIT-like monoclonal antibody. Blood. 99:2002;1230-1236.
19. Bacsi S., De Palma R., Visentin G.P., Gorski J., Aster R.H. Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis. Blood. 94:(1):1999;208-215.
20. Denomme G.A., Warkentin T.E., Horsewood P., Sheppard J.A., Warner M.N., Kelton J.G. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the FcγRIIa 'low responder' (his131) gene in patients with heparin-induced thrombocytopenia. J. Lab. Clin. Med. 130:(3):1997;278-284.
21. Amiral J., Bridey F., Wolf M., et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb. Haemost. 73:(1):1995;21-28.
22. Horne M.K. III, Hutchison K.J. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am. J. Hematol. 58:(1):1998;24-30.
23. Greinacher A., Potzsch B., Amiral J., Dummel V., Eichner A., Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb. Haemost. 71:(2):1994;247-251.
24. Files J.C., Malpass T.W., Yee E.K., Ritchie J.L., Harker L.A. Studies of human platelet α-granule release in vivo. Blood. 58:1981;607-618.
25. Cines D.B., Tomaski A., Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N. Engl. J. Med. 316:(10):1987;581-589.
26. Reilly M.P., Taylor S.M., Hartman N.K., et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcγRIIA. Blood. 98:(8):2001;2442-2447.
27. Trikalinos T.A., Karassa F.B., Ioannidis J.P. Meta-analysis of the association between low-affinity Fcγ receptor gene polymorphisms and hematologic and autoimmune disease. Blood. 98:(5):2001;1634-1635.
28. Blank M., Cines D.B., Arepally G., Eldor A., Afek A., Shoenfeld Y. Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. Clin. Exp. Immunol. 108:(2):1997;333-339.
29. Visentin G.P., Ford S.E., Scott J.P., Aster R.H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J. Clin. Invest. 93:(1):1994;81-88.
30. Herbert J.M., Savi P., Jeske W.P., Walenga J.M. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb. Haemost. 80:(2):1998;326-331.
31. Pouplard C., Iochmann S., Renard M., et al. Induction of monocyte tissue factor expression by antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia. Blood. 96:(11):2000;530a.
32. Arepally G.M., Mayer I.M. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood. 98:(4):2001;1252-1254.
33. Warkentin T.E. Heparin-induced skin lesions. Br. J. Haematol. 92:(2):1996;494-497.
34. Wallis D.E., Quintos R., Wehrmacher W., et al. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest. 116:(5):1999;1333-1338.
35. Chong B.H., Magnani H.N. Danaparoid for the treatment of heparin-induced thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia. 2nd ed. 2001;323-348 Dekker, New York.
36. Greinacher A., Volpel H., Janssens U., et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 99:(1):1999;73-80.
37. Lewis B.E., Wallis D.E., Berkowitz S.D., et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 103:(14):2001;1838-1843.